12797 Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial

Autor:	Charles Lynde, Diamant Thaçi, Monika Liljedahl, Mark Lebwohl, Anja Snel-Prentø, Jean-Philippe Lacour, Marie Holst Mørch, Richard B. Warren
Rok vydání:	2020
Předmět:	medicine.medical_specialty business.industry Fixed-dose combination Urology Betamethasone dipropionate Dermatology medicine.disease law.invention Randomized controlled trial law Psoriasis Calcipotriene medicine In patient business medicine.drug
Zdroj:	Journal of the American Academy of Dermatology. 83:AB1
ISSN:	0190-9622
DOI:	10.1016/j.jaad.2020.06.091
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6f32254ff55f36334e4bb9dee470b0ed https://doi.org/10.1016/j.jaad.2020.06.091 Zobrazit plný text záznamu Full Text from ScienceDirect